Market Insights

Gene Therapy’s Reality Check | Ep. 988

Curative Science Meets a Broken System

Apr 23

Why Mental Health Drug Development Keeps Failing | Ep. 983

That’s About to Break

Apr 17

The FDA Is Not the Bottleneck. Companies Are | Ep. 973

Execution fails. The FDA just reveals it.

Apr 2

The Cost of Capital Regime | Ep. 968

Why legible therapeutics now command the premium

Mar 26

The Assets Pharma Actually Wants | Ep. 962

Why Mitochondria Are Becoming a Drug Platform

Mar 19

The Organelle That Writes the Stress Response | Ep. 956

Why Mitochondria Are Becoming a Drug Platform

Mar 12

Ribosomes as Drug Targets. The Quiet Rewrite of Psychiatry and Beyond. | Ep. 950

Therapeutics will be defined by translational pulse, not receptor binding.

Mar 5

Higher Cost of Capital. Tighter Private Biotech. | Ep. 944

How structural compression changed round size, timelines, and exits

Feb 26

The Public Playbook for Translating Science Into Therapeutics | Ep. 938

The Capital Markets Just Redefined What Translation Means

Feb 19

The Catalyst Machine | Ep. 931

How Capital Markets Quietly Rewired Translational Therapeutics

Feb 12

Liquidity Is the New Biology | Ep. 925

What the VC Data Quietly Says About the Future of Translational Biotech

Feb 5

Recycling Risk Capital | Ep. 918

Why 2026 Reopens Biotech and How Translation Wins

Jan 29

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts